Table 2.
Newborn characteristics and substance exposure (n = 222)
| Age, median (IQR), days | 3.0 (1.0–4.0) |
| Sex | |
| Male, n (%) | 118 (53.2) |
| Race/ethnicity (n = 212), n (%) | |
| White or Caucasian | 144 (67.9) |
| Hispanic or Latino | 58 (27.4) |
| Black or African American | 6 (2.8) |
| Asian or Pacific Islander | 2 (0.9) |
| Presence of withdrawal, n (%) | |
| Yes | 111 (50.0) |
| Pharmacologically treated for withdrawal or NAS (n = 111), n (%) | |
| Yes | 71 (64.0) |
| MDS positive results, n (%) | |
| Amphetamines | 47 (21.2) |
| If + for Amphetamines, did it include methamphetamine? (n = 47) (Yes) | 44 (93.6) |
| Barbiturates | 5 (2.3) |
| Benzodiazepines | 6 (2.7) |
| Buprenorphine | 65 (29.3) |
| Cannabinoids | 72 (32.4) |
| Cocaine | 20 (9.0) |
| Methadone | 64 (28.8) |
| Opiates | 45 (20.3) |
| Phencyclidine | 0 |
| Negative/None | 16 (7.2) |
| Unavailable | 3 (1.4) |
| Disposition at discharge, n (%) | |
| Home | 192 (86.5) |
| Foster care | 27 (12.2) |
| Transfer | 3 (1.4) |
| Death | 0 |
IQR interquartile range, NAS neonatal abstinence syndrome, MDS meconium drug screening